DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» OncoMed
OncoMed
2019 Breakthrough Summit Co-Host Committee 2019 Breakthrough
Next Generation Immuno-Oncology Targeting Hot and Cold Tumors
IGNYTE-ESO: a Master Protocol to Assess Safety and Activity of Letetresgene Autoleucel (Lete-Cel; GSK3377794) Victoria L
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Feasibility and First Reports of the MATCH-R Repeated Biopsy Trial At
Compugen Ltd. (Exact Name of Registrant As Specified in Its Charter and Translation of Registrant's Name Into English) ______
Steady Course Or Changing Tides? 2015 Trial Starts 2016 Clinical Trials Roundup – Steady Course Or Changing Tides?
Understanding Life Science Partnership Structures
2019 Best of ASCO Planning Committee All Relationships Are Considered Compensated
Annual Report 2017
13Th Annual Oncology Grand Rounds
2021 Quality Care Symposium Planning Committee All Relationships Are Considered Compensated
Precision Medicine
Company Update August 27, 2013
Phase II Two-Arm Study of Tepotinib + Osimertinib in Patients with EGFR-Mutant NSCLC and Acquired
Oncomed Gets Its Groove Back with Big Celgene Deal
2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated
Celgene's Multibillion Spree on Oncomed/NYC
Top View
Disclosure Summary
View Annual Report
(BYL719) in PIK3CA-Altered Solid Tumors: Results from the First-In-Human Study Dejan Juric, Jordi Rodon, Josep Tabernero, Filip Janku, Howard A
Oncomed Pharmaceuticals Inc
Oramed Pharmaceuticals, Inc. Rating
Presented at the American Association for Cancer Research (AACR), Atlanta, GA, USA
Dilpacimab (ABT-165) Manuscript Resubmission-2 July 7, 2021
Volunteer Disclosure Report
Meet the Professor